Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

196.64
+0.72000.37%
Volume:955.53K
Turnover:190.74M
Market Cap:42.15B
PE:-22.04
High:202.02
Open:198.53
Low:196.02
Close:195.92
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:0.99
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.17
PE(LYR):-33.05

Loading ...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Satellos Bioscience (MSLE) and Intuitive Surgical (ISRG)

TIPRANKS
·
Jul 09

Revolution Medicines price target raised to $235 from $205 at Guggenheim

TIPRANKS
·
Jul 09

Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich?

Simply Wall St.
·
Jul 09

RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial

TIPRANKS
·
Jul 09

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

THOMSON REUTERS
·
Jul 07

Revolution Medicines Rises as EU Regulator Starts Phased Review of Cancer Drug

Reuters
·
Jul 07

EMA Fast Tracks Review of Medicine for Metastatic Pancreatic Cancer

Reuters
·
Jul 07

Ema - Begins Phased Review of Daraxonrasib for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jul 07

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), AxoGen (AXGN) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 06

Revolution Medicines is Maintained at Outperform by Mizuho

Dow Jones
·
Jul 06

Revolution Medicines Inc : Mizuho Raises Target Price to $215 from $185

THOMSON REUTERS
·
Jul 06

Wedbush Raises Price Target on Revolution Medicines to $181 From $165, Keeps Outperform Rating

MT Newswires Live
·
Jul 06

Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?

Simply Wall St.
·
Jul 06

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Johnson & Johnson (JNJ)

TIPRANKS
·
Jul 04

Revolution Medicines is Maintained at Outperform by Wedbush

Dow Jones
·
Jul 03

Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target

TIPRANKS
·
Jul 03

Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results

Dow Jones
·
Jul 02

Revolution Medicines Reports Release Available on Zoldonrasib Combination Data in RAS G12D Metastatic Pancreatic Cancer

Reuters
·
Jul 02

Revolution Medicines Director Sushil Patel Disposes of 5,580 Common Shares Worth $1.04 Million

Reuters
·
Jul 02

Revolution Medicines is Maintained at Buy by Truist Securities

Dow Jones
·
Jun 30